US6700024010

Povijest Novavax EBIT

GODINA	EBIT (undefined USD)
2029e	-
2028e	11,73
2027e	−18,82
2026e	−101,77
2025e	−119,75
2024e	21,51
2023	−552,21
2022	−644,70
2021	−1.686,60
2020	−416,70
2019	−129,60
2018	−173,90
2017	−171,70
2016	−269,10
2015	−157,20
2014	−83,70
2013	−52,40
2012	−29,70
2011	−21,60
2010	−38,50
2009	−37,40
2008	−34,40
2007	−30,30
2006	−21,10
2005	−15,20
2004	−34,90

Novavax Aktienanalyse

Što radi Novavax?

Novavax Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines and products for the treatment of infectious diseases. The company was founded in 1987 in Maryland, USA, and has since relocated its headquarters to Gaithersburg, Maryland. Novavax is a pioneer in vaccine technology. The company's business model is based on the development of vaccines for diseases such as malaria, Zika, RSV, and COVID-19. Novavax uses the latest technology and methods to ensure the highest efficacy and safety of its vaccines. By licensing its own technologies and licenses, the company has significantly increased its reach and effectiveness, establishing successful partnerships with institutions such as the Bill and Melinda Gates Foundation and the US Department of Defense. The different divisions of the company are focused on the development of vaccines and antiviral therapies. Novavax is involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Currently, Novavax is conducting studies in the field of Respiratory Syncytial Virus (RSV) vaccination. The RSV program is Novavax's oldest program, launched in 1995, and the company has developed several vaccine candidates. A recent Phase III trial of an RSV vaccine candidate for the prevention of RSV infections in pregnant women did not meet its goals. However, it is a key position in vaccine development, allowing the company to focus on the development of vaccines against other infectious diseases. Novavax also has an ongoing research program focused on developing a COVID-19 vaccine candidate based on a protein called Nanoparticle Spike Protein (NVX-CoV2373) expressed in insect cells. A major advantage of this program is that it allows for faster manufacture of millions of doses with high throughput and has consistently shown positive results in clinical studies. The company has also developed a revolutionary technology called Matrix-M, which is used in its vaccines to enhance the immune response and activity against the vaccine. It is an adjuvant technology that stimulates the body to respond to a vaccine and achieve higher immunity against the pathogen. Novavax has a number of vaccine candidates in clinical development, including vaccines against malaria, influenza, and human papillomavirus (HPV), as well as an antiviral therapy for the treatment of RSV. These programs are still in the early stages of development, but the company is confident that it will be successful in the future. Overall, Novavax is a company specializing in the development of innovative vaccines and antiviral therapies for the treatment of infectious diseases. With a focus on safety, efficacy, and innovation, the company has achieved a leading position in vaccine technology and has become a key player in the global health landscape. Answer: Novavax is a biopharmaceutical company that specializes in developing and marketing innovative vaccines and products for treating infectious diseases. It was founded in 1987 in Maryland, USA, and focuses on developing vaccines against diseases like malaria, Zika, RSV, and COVID-19. The company uses advanced technology and methods to ensure the effectiveness and safety of its vaccines. It has partnerships with institutions like the Bill and Melinda Gates Foundation and the US Department of Defense. Novavax is also involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Its oldest program is focused on developing an RSV vaccine, and it also has a program focused on developing a COVID-19 vaccine. Novavax has developed a technology called Matrix-M, which enhances the immune response to vaccines. It also has vaccine candidates in development for malaria, influenza, and HPV, as well as an antiviral therapy for RSV. Overall, Novavax is a leading company in vaccine technology and aims to develop effective and innovative vaccines and antiviral therapies for infectious diseases. Novavax ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT u detalje

Analiza EBIT-a od Novavax

EBIT (Dobit prije kamata i poreza) od Novavax predstavlja operativnu dobit poduzeća. Izračunava se oduzimanjem svih poslovnih rashoda, uključujući troškove prodanih roba (COGS) i operativnih troškova, od ukupnog prihoda, ali ne uzimajući u obzir kamate i poreze. Pruža uvid u operativnu profitabilnost poduzeća bez utjecaja financijske strukture i poreza.

Usporedba godina za godinom

Godišnja usporedba EBIT-a od Novavax može pokazati trendove u operativnoj efikasnosti i profitabilnosti poduzeća. Povećanje EBIT-a kroz godine može ukazivati na poboljšanu operativnu efikasnost ili rast prihoda, dok smanjenje može izazvati zabrinutost zbog povećanih poslovnih troškova ili padajućih prihoda.

Utjecaj na investicije

EBIT od Novavax je važna mjerna veličina za investitore. Pozitivan EBIT ukazuje da poduzeće generira dovoljno prihoda da pokrije svoje operativne troškove, ključni aspekt u ocjenjivanju financijskog zdravlja i stabilnosti poduzeća. Investitori pažljivo prate EBIT kako bi procijenili profitabilnost i potencijal za budući rast poduzeća.

Interpretacija fluktuacija EBIT-a

Fluktuacije u EBIT-u od Novavax mogu biti posljedica promjena u prihodima, operativnim troškovima ili oboje. Rastući EBIT ukazuje na poboljšanje operativne učinkovitosti ili povećane prodaje, dok padajući EBIT može ukazivati na rastuće operativne troškove ili smanjene prihode, što može zahtijevati potrebu za strateškom prilagodbom.

Česta pitanja o Novavax dionici

Koliko je Novavax ostvario EBIT-a za tekuću godinu?

U tekućoj godini Novavax je ostvario EBIT od 21,51 mil. USD.

Što je EBIT?

EBIT označava Earnings Before Interest and Taxes i odnosi se na dobit prije kamata i poreza poduzeća Novavax.

Kako se EBIT od Novavax razvijao tijekom posljednjih godina?

EBIT od Novavax je u usporedbi s prošlom godinom porastao za −103,895% pao.

Što EBIT znači za investitore?

EBIT daje ulagačima uvid u profitabilnost poduzeća, jer prikazuje dobit prije kamata i poreza.

Zašto je EBIT važan pokazatelj za investitore?

EBIT pruža izravniji uvid u profit poduzeća nego neto dobit, stoga je to važan pokazatelj za investitore za procjenu profitabilnosti poduzeća.

Zašto variraju EBIT vrijednosti?

EBIT vrijednosti mogu varirati jer ih mogu utjecati različiti faktori, na primjer promet, troškovi i efekti poreza.

Koju ulogu igra porezno opterećenje kod EBIT-a?

Porezna opterećenja imaju izravan utjecaj na EBIT poduzeća, jer se oduzimaju od dobiti.

Kako se EBIT prikazuje u financijskom izvještaju poduzeća Novavax?

EBIT od Novavax nalazi se u izvještaju o dobiti i gubitku.

Može li se EBIT koristiti kao pojedinačni indikator za vrednovanje poduzeća?

EBIT je važan pokazatelj pri procjeni poduzeća, no trebalo bi dodatno razmotriti i druge financijske pokazatelje kako bi se dobila sveobuhvatna slika.

Zašto EBIT nije isto što i neto dobit?

Neto dobit poduzeća uključuje poreze i kamate, dok EBIT predstavlja samo dobit prije kamata i poreza.

Koliko dividende plaća Novavax?

U posljednjih 12 mjeseci Novavax je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Novavax će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Kolika je dividendna prinosa od Novavax?

Trenutni prinos dividende od Novavax iznosi .

Kada Novavax isplaćuje dividendu?

Novavax isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Koliko je sigurna dividenda od Novavax?

Novavax je isplatio dividendu svake godine u posljednjih 0 godina.

Kolika je dividenda od Novavax?

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kojem se sektoru nalazi Novavax?

Novavax se pripisuje sektoru 'Zdravlje'.

Wann musste ich die Aktien von Novavax kaufen, um die vorherige Dividende zu erhalten?

Da bi primili posljednju dividendu od Novavax od 17. 05. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 17. 05. 2024..

Kada je Novavax isplatio posljednju dividendu?

Posljednja isplata dividende izvršena je 17. 05. 2024..

Kolika je bila dividenda Novavax u godini 2023?

U godini 2023 su od Novavax 0 USD isplaćene kao dividende.

U kojoj valuti Novavax isplaćuje dividendu?

Dividende od Novavax isplaćuju se u USD.

Novavax EBIT 2024

Novavax EBIT

Novavax Dividendski prinos

Ticker

ISIN

WKN

U godini 2024 EBIT kompanije Novavax iznosio je 21,51 mil. USD, što je porast od −103,90% u odnosu na −552,21 mil. USD EBIT prethodne godine.